PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model

PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics

(2018) Margarita Udall et al.   Diagnostic Pathology

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

(2018) Rosemarie Tremblay-LeMay et al.   Journal of Hematology & Oncology

FDA analysis of pembrolizumab trials in multiple myeloma: Immune related adverse events (irAEs) and response.

(2018) Aviva C Krauss et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 expression in tumor cells is an independent unfavorable prognostic factor in oral squamous cell carcinoma

(2018) Juan C de Vicente et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma

(2018) Tomas Jelinek et al.   Frontiers in Immunology

Soluble immune checkpoints in cancer: production, function and biological significance

(2018) Daqian Gu et al.   Journal for ImmunoTherapy of Cancer

Prognostic significance of PD-L1 in solid tumor

(2017) Qianqian Wang et al.   MEDICINE

Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?

(2016) Jacalyn Rosenblatt et al.   BLOOD

Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients

(2016) E. R. Parra et al.   CLINICAL CANCER RESEARCH

Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma

(2016) S. Yokoyama et al.   CLINICAL CANCER RESEARCH

PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival

(2016) Marion Four et al.   HEMATOLOGICAL ONCOLOGY

PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas

(2016) Aaron Goodman et al.   Nature Reviews Clinical Oncology

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma

(2016) Shang-Yi Huang et al.   Oncotarget

Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy

(2015) M. V. Dhodapkar et al.   BLOOD

Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma

(2015) J. Kiyasu et al.   BLOOD

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

(2015) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma

(2015) B Paiva et al.   LEUKEMIA

Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients

(2015) S Yousef et al.   Blood Cancer Journal

Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma

(2015) Liang Wang et al.   Oncotarget

Effects of tissue decalcification on the quantification of breast cancer biomarkers by digital image analysis

(2014) Arkadiusz Gertych et al.   Diagnostic Pathology

The role of B7 family molecules in hematologic malignancy

(2012) P. Greaves et al.   BLOOD

Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma

(2012) H Tamura et al.   LEUKEMIA

Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade

(2011) William H.D. Hallett et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

SHOULD I USE THIS NOMOGRAM?

(2008) Michael W. Kattan   BJU INTERNATIONAL